Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT02621944
EARLY_PHASE1

Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia

Sponsor: University of Florida

View on ClinicalTrials.gov

Summary

Hypoxic-Ischemic Encephalopathy (HIE) occurs in 20 per 1000 births. Only 47% of neonates treated with the state of the art therapy (induced systemic hypothermia) have normal outcomes. Therefore, other promising therapies that potentially work in synergy with hypothermia to improve neurologic outcomes need to be tested. One potential agent is melatonin. Melatonin is a naturally occurring substance produced mainly from the pineal gland. Melatonin is widely known for its role in regulating the circadian rhythm, but it has many other effects that may benefit infants with HI injury. Melatonin serves as a free radical scavenger, decreases inflammatory cytokines, and stimulates anti-oxidant enzymes. Therefore, melatonin may interrupt several key components in the pathophysiology of HIE, in turn minimizing cell death and improving outcomes. The research study will evaluate the neuroprotective properties and appropriate dose of Melatonin to give to infants undergoing therapeutic hypothermia for hypoxic ischemic encephalopathy.

Key Details

Gender

All

Age Range

Any - 6 Hours

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2016-11

Completion Date

2026-03

Last Updated

2025-10-02

Healthy Volunteers

No

Interventions

DRUG

Melatonin

Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.

OTHER

Magnetic Resonance Imaging

All participants will receive an MRI between 7-12 days of age.

OTHER

Pharmacokinetics

All participants will receive pharmacokinetics to test the amount of melatonin in the blood.

BEHAVIORAL

Neurological Outcome Assessment

All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.

Locations (2)

University of Florida

Gainesville, Florida, United States

Florida Hospital for Children

Orlando, Florida, United States